Hepatic Nuclear Factor 1-α Directs Nucleosomal Hyperacetylation to Its Tissue-Specific Transcriptional Targets

Abstract

Mutations in the gene encoding hepatic nuclear factor 1-α (HNF1-α) cause a subtype of human diabetes resulting from selective pancreatic β-cell dysfunction. We have analyzed mice lacking HNF1-α to study how this protein controls β-cell-specific transcription in vivo. We show that HNF1-α is essential for the expression ofglut2 glucose transporter and L-type pyruvate kinase (pklr) genes in pancreatic insulin-producing cells, whereas in liver, kidney, or duodenum tissue, glut2 andpklr expression is maintained in the absence of HNF1-α. HNF1-α nevertheless occupies the endogenous glut2 andpklr promoters in both pancreatic islet and liver cells. However, it is indispensable for hyperacetylation of histones in glut2 and pklr promoter nucleosomes in pancreatic islets but not in liver cells, where glut2 andpklr chromatin remains hyperacetylated in the absence of HNF1-α. In contrast, the phenylalanine hydroxylase promoter requires HNF1-α for transcriptional activity and localized histone hyperacetylation only in liver tissue. Thus, different HNF1-α target genes have distinct requirements for HNF1-α in either pancreatic β-cells or liver cells. The results indicate that HNF1-α occupies target gene promoters in diverse tissues but plays an obligate role in transcriptional activation only in cellular- and promoter-specific contexts in which it is required to recruit histone acetylase activity. These findings provide genetic evidence based on a live mammalian system to establish that a single activator can be essential to direct nucleosomal hyperacetylation to transcriptional targets.

ACKNOWLEDGMENTS

We are indebted to Frank Gonzalez and D. LeRoith for providing us with hnf1-α null mice and B. Thorens, J. Habener, and C. Van Schravendijk, who provided us with antisera. We are grateful to M. Vallejo for critical reading of the manuscript, J. Habener for helpful comments, P. Farnham for providing us with a chromatin immunoprecipitation protocol, and E. Vilardell for valuable support.

This work was supported by SAF98-0005 (CICYT), FundacióMarató TV3, Eli Lilly/European Association for the Study of Diabetes, and QLRT1999-546 (European Commission) (J.F.). M.P. is the recipient of a postdoctoral fellowship from the CICYT.